Role of isotope selection in long-term outcomes in patients with intermediate-risk prostate cancer treated with a combination of external beam radiotherapy and low-dose-rate interstitial brachytherapy Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Iodine Radioisotopes
  • Neoplasm Recurrence, Local
  • Palladium
  • Prostatic Neoplasms

abstract

  • (125)I renders a superior rate of BRFS compared with (103)Pd when used with EBRT. Hormonal therapy does not provide additional benefit in patients with intermediate-risk prostate cancer treated with a combination of EBRT and brachytherapy, except for the addition of hormonal therapy to (103)Pd.

publication date

  • May 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3623292

Digital Object Identifier (DOI)

  • 10.1016/j.urology.2012.01.043

PubMed ID

  • 22546388

Additional Document Info

start page

  • 1098

end page

  • 104

volume

  • 79

number

  • 5